To illustrate the feasibility of this approach in a clinical study, we used total RNA extracted from FACS-derived primary CD5+CD19+ (CD5+) and CD5−CD19+ (CD5−) cells from a single chronic lymphocytic leukemia (CLL) patient to establish the workflow and custom analysis. Here, CD19 is linked to B-cell chronic lymphocytic leukemia.